CliffBio
small molecule

TEPYLUTE

THIOTEPA

Loss of exclusivityAugust 2041latest FDA-listed patent expiry
CompanyShorla Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameTEPYLUTE
Active ingredientTHIOTEPA
Strength15MG/1.5ML (10MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJune 2024
Marketing statusRX

Listed patents

PatentExpiresType
12622921August 2041use U-4530
11975013August 2041product

More from Shorla Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.